Anti-IL1RA antibody (ab2573)

Overview

• Product nameAnti-IL1RA antibodySee all IL1RA primary antibodies ...
• Description
  Rabbit polyclonal to IL1RA
• SpecificityThis antibody does not recognize human IL-1 alpha , IL-1 beta or IL-1 receptor type I or type II. It is primarily directed against the secreted form of IL-1Ra (also termed sIL-1Ra) but recognizes the native (non-denatured) as well as denatured intracellular form of IL-1Ra (also termed icIL-1Ra).
• Tested applicationsICC/IF, ELISA, Flow Cyt, IHC-P, IHC-Fr, Neutralising, RIA, WB more details
• Species reactivity
  Reacts with: Human
  Predicted to work with: Non Human Primates

  Does not react with

  Mouse, Rabbit
• Immunogen

  Recombinant human IL-1Ra produced in E.coli.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.01% Sodium Azide
  Constituents: 0.15M Sodium chloride, 0.02M Potassium phosphate, pH 7.2
• Concentration information loading...
• PurityIgG fraction
• Purification notesSterile filtered, no stabilizer. Endotoxin Content: <10 pg/ml by LAL method.
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Immunology
  • Innate Immunity
  • Cytokines
  • Interleukins

Applications

Target

• FunctionInhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure.
• Tissue specificityThe intracellular form of IL1RN is predominantly expressed in epithelial cells.
• Involvement in diseaseGenetic variation in IL1RN is associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4) [MIM:612628]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  Defects in IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) [MIM:612852]; also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T-cells. DIRA is a rare, autosomal recessive, genetic autoinflammatory disease that results in sterile multifocal osteomyelitis (bone inflammation in multiple places), periostitis (inflammation of the membrane surrounding the bones), and pustulosis (due to skin inflammation) from birth.
• Cellular localizationCytoplasm and Secreted.

Target information above from: UniProt accession P18510 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 3557 Human
  • Omim: 147679 Human
  • SwissProt: P18510 Human
  • Unigene: 81134 Human

• Alternative names
  DIRA antibodyICIL 1RA antibodyICIL-1RA antibody

  ICIL1RA antibodyIL-1ra antibodyIL-1ra3 antibodyIL-1RN antibodyIL1 inhibitor antibodyIL1F3 antibodyIL1RA antibodyIL1RA_HUMAN antibodyIL1RN (IL1F3) antibodyIL1RN antibodyInterleukin 1 receptor antagonist antibodyInterleukin-1 receptor antagonist protein antibodyIntracellular IL 1 receptor antagonist type II antibodyIntracellular interleukin 1 receptor antagonist (icIL 1ra) antibodyIRAP antibodyMGC10430 antibodyMVCD4 antibodyType II interleukin 1 receptor antagonist antibody

  see all

Anti-IL1RA antibody images

• 

  Immunocytochemistry/ Immunofluorescence - Anti-IL1RA antibody (ab2573)
  ICC/IF image of ab2573 stained MCF-7 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab2573, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
• 

  Western blot - Anti-IL1RA antibody (ab2573)
  Anti-IL1RA antibody (ab2573) at 1 µg/ml + A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg
  
  Secondary
  Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), pre-adsorbed (ab97080) at 1/5000 dilution
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Predicted band size : 20 kDa
  
  
  Exposure time : 3 minutes
• 

  Western blot
  Anti-IL1RA antibody (ab2573) at 1 µg/ml + IL1RA antagonist protein (ab50081) at 0.01 µg
  
  Secondary
  Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), pre-adsorbed (ab97080) at 1/5000 dilution
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Exposure time : 20 seconds

Protocols

• Neutralization guidelines